HIV testing policies for migrants and ethnic minorities in EU/EFTA Member States

Debora Alvarez-del Arco1,2, Susana Monge1,2, Ana M. Caro-Murillo1, Oriana Ramirez-Rubio1, Amaya Azcoaga-Lorenzo3, Maria J. Belza4, Yaiza Rivero-Montesdeoca1, Teymur Noori5, Julia Del Amo1, the Study Working Group*

1 National Centre of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
2 Division of Environmental and Reproductive Epidemiology, Biomedical Research Network on Epidemiology and Public Health (CIBERESP), Spain
3 Department of Health Sciences. Universidad Rey Juan Carlos I, Madrid, Spain
4 National School of Public Health, Instituto de Salud Carlos III, Madrid, Spain
5 European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

*Appendix 1.

Correspondence: Débora Álvarez del Arco, National Centre of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain, Tel: +34 918222196, Fax: +34 913877515, e-mail: dalvarez@isciii.es

Introduction

The HIV epidemic is a major public health problem in Europe; 27,116 newly diagnosed cases of HIV infection were reported in 2010 by 28 countries of the European Union and European Economic Area (EU/EEA). Migrant populations, largely from Sub-Saharan Africa (SSA), represent a considerable proportion of AIDS cases and HIV infections, especially among women. Also, migrants are considered an important sub-population in the national response to HIV in most countries of the European Union and the European Free Trade Association (EU/EFTA). Definitions of migrants and ethnic minorities are heterogeneous between and within countries and throughout the different time periods, showing the lack of a standardized definition that is valid for any context. Migrants and ethnic minorities are not equivalent in term of populations although some migrants become part of established ethnic minorities.

Most migrant groups, specially people of sub-Saharan African origin, have higher rates of late HIV diagnosis and, to some extent, the decline in AIDS incidence that followed the advent of combined Antiretroviral Therapy (cART) has not been observed. Barriers for migrants to access HIV testing and care can be placed at individual, health services, community and structural levels. Although migrants may share some of these barriers with disadvantaged native-born subjects, including ethnic minorities, those related to administrative and legal status affect migrants differently, establishing a population subgroup different to the native-born. Furthermore, some countries in the European context do not provide HIV care for people of uncertain legal status.

The European Centre for Disease Prevention and Control (ECDC) issued its HIV testing Guidelines in December 2010 and recommended that all migrants from countries with high HIV prevalence should be offered an HIV test under the premises that testing should be voluntary, confidential and undertaken after previous informed consent. These guidelines acknowledge that the single biggest benefit of HIV testing is access to treatment and that the provision of cART should be the cornerstone of national HIV testing strategies. However, there may be vast differences in HIV testing policies between EU/EFTA country which are, ultimately, the ones that dictate local practice. We aim to describe recommendations and its rationale regarding HIV testing and counselling for migrants and ethnic minorities issued by the EU/ EFTA Member States up to the publication of the ECDC HIV testing Guidelines in December 2010.
Methods

An online survey was conducted among 31 EU/EFTA Member States. Key informants were selected by ECDC within the competent health authorities (Ministries of Health and Public Health institutions) listed in the Appendix (Supplementary File S1). The survey inquired on the existence of specific HIV testing and counselling recommendations or policies for migrants and/or ethnic minorities and the year of their publication. Respondents were also asked to provide the most up-to-date document containing these recommendations. Various e-mail reminders were sent to encourage participation between February and September 2010. Overall, 29 (94%) countries responded. Data on participating countries are provided in the Appendix (Supplementary File S1).

We performed an additional search in the web pages of the different competent bodies of the EU/EFTA Member States (National AIDS Plans, Ministries of Health, Public Health Agencies, etc.) for national recommendations, guidelines or any other policy documents. Retrieved documents are listed in the Appendix (Supplementary File S2).

A data extraction form was designed and piloted. Teams of two independent researchers read the documents and extracted information on the publication date, issuing body and type of document (guidelines, health plan, piece of legislation, etc.). The data extraction form also contained information on the rationale for HIV testing at individual and community levels, on the definition of migrants and ethnic minorities, on whether their vulnerability to HIV infection was acknowledged, and/or if these populations were identified as groups to be offered HIV testing. Information on the frequency and the site for HIV testing was recorded as well as recommendations for pre- and post-test counselling. Special attention was paid to whether the country recommended HIV testing on arrival of migrants and to any reference to the legal consequences of testing.

Additional collaboration of the national representatives was requested when the documents were in languages different to English, French, German, Italian, Portuguese or Spanish. However, in three central European countries, documents could not be reviewed and only responses from national key informants were used.

Results

Research flow chart is described in figure 1. Overall, 28 documents from 27 EU/EFTA Member States were identified: sixteen HIV/AIDS National Strategies, three HIV testing Guidelines, four miscellaneous documents about HIV testing recommendations, two internal working documents, one piece of legislation, one National Strategy on Communicable Diseases and one national communicable diseases surveillance bulletin.

Rationale for early HIV testing

Documents from seven countries (Denmark, France, Norway, Portugal, Spain, Switzerland and the UK) discuss the benefits of early HIV diagnosis at individual and community levels when testing is linked to adequate referral to specialized services and treatment. Reduction in HIV viral replication and decreased HIV transmission from patients on treatment is presented as part of the rationale. Testing and counselling are also reported to be linked to positive behavioural change, although the French Guidelines remind this has only been documented for HIV-positive individuals. The UK Guidelines describe long pre-counselling as not necessary and recommends replacing it by brief pre-test information addressing the benefits of testing, its voluntary nature and the request of informed consent.

Migrants and ethnic minorities as vulnerable populations for HIV

In these documents, migrants are mainly defined based on their region of origin. Overall, 22 of the 31 countries (71%) identify migrants as populations at risk for HIV infection (table 1) and specifically mention people from high HIV prevalence regions such as SSA and the Caribbean, and some specific groups from Eastern Europe, Asia and South America. Some documents only use the term 'migrant', and fewer documents refer to ethnic minorities. Only Bulgaria, Slovakia, Romania and the UK identify ethnic minorities as vulnerable to HIV. The Romanian Guidelines published in 2007 explicitly acknowledge the vulnerability of Roma people, given their high prevalence of risk contexts and behaviours; the Bulgarian HIV National Program also supports this, and the Slovakian program goes as far as to consider Roma...
community as part of marginalized groups coming from different ethnic or social environments. Black and minority ethnic groups (BME) are identified as vulnerable for HIV infection in the UK National Strategy although the UK National Guidelines of HIV Testing 2008 does not identify ethnic minorities as vulnerable to HIV.

Four documents (from France, Italy, Spain and the UK) mention the higher proportion of delayed HIV diagnosis in migrants, attributed to barriers to access health care such as stigma, lack of community support, isolation, racism and double discrimination for being an HIV-positive migrant. Cultural aspects, for instance religion and language, are described as additional barriers to access prevention and care. A disadvantaged socio-economic situation (poverty, low education, unemployment or poor working conditions) is also taken into account in a number of documents together with the higher vulnerability of some migrant women owing to low social status and double moral standards to judge female and male sexual behaviour. The French Guidelines and the Spanish Plan on HIV/AIDS describe how women may be exposed to testing. The German Guidelines state migrants of uncertain origin from sub-Saharan Africa and the Caribbean.

HIV testing recommendations addressing migrants and ethnic minorities

Even though 22 country key informants or national documents explicitly acknowledged that migrants were vulnerable to HIV infection (table 1), six of them—Germany, Ireland, Italy, Malta, Portugal and Spain—do not explicitly recommend HIV testing for migrants (table 2). Overall, 16 countries recommend HIV testing in migrant population whereas none recommends it in the case of ethnic minorities. Table 3 describes the groups specifically mentioned in each country’s document to be offered testing. Some countries refer generically to ‘migrant populations’ whereas others are more specific and limit the recommendation to migrants originating from high prevalence countries.

The recommended frequency of HIV testing for migrants is specified in documents from Denmark, France and the UK. Denmark recommends testing on the first contact with the health care system regardless of the reason, while France and the UK recommend systematic screening for people originating from regions of high HIV prevalence. French Guidelines also suggest repeating HIV testing every year for persons with multiple partners originating from sub-Saharan Africa and the Caribbean.

Documents from various countries (Belgium, Bulgaria, France, Luxembourg, Norway, Portugal, Romania, Spain, Switzerland and the UK) highlight the importance of identifying the most appropriate setting and the need to broaden the scope of health services performing the test to be able to scale up HIV testing in migrant populations. Accordingly, documents from Belgium, Bulgaria, France, Norway, Portugal, Spain, Switzerland and the UK state the benefits of HIV testing in community settings where people who would not be accessed through conventional services can be reached. In this regard, NGOs and Community-Based Organizations (CBOs) are settings explicitly identified as suitable. The use of rapid HIV tests in community settings is also mentioned in six documents (Bulgaria, France, Portugal, Spain, Switzerland and the UK) as being progressively accepted to increase HIV testing uptake in people who would not be reached otherwise.

Legal consequences of HIV testing for migrants

Fear that disclosure of HIV status would affect migrant status and Visa application process is mentioned in Ireland as a deterrent to testing. The German Guidelines state migrants of uncertain
status involved in a deportation process will not be deported if antiretroviral treatment is not available in their home country. In France, a law allows irregular migrants to obtain the residence permit if they are diagnosed with a serious disease as HIV and treatment is not accessible in their country of origin. Iceland, Poland and Slovakia offer HIV testing on arrival as part of general health screening claimed to provide early and appropriate HIV counselling, referral and care. In Slovakia, all foreigners staying for a period >3 months owing to studies or work are required to undergo an HIV test. An HIV-negative result is required for their sojourn permit, and they can be requested to undergo HIV testing by the police if they cannot provide a document confirming HIV negativity.

### Discussion

Although >68% of the policy documents from the 31 EU/EFTA Member States identify migrants as a vulnerable population for HIV infection, only 52% recommend HIV testing for migrant populations. The definitions and concepts of the terms migrants and ethnic minorities are extremely heterogeneous in the various policy documents retrieved. Some countries refer to migrants while others provide more detail—migrants from HIV endemic countries, migrants from Sub-Saharan Africa, etc. Ethnic minorities are not mentioned in general as groups most at risk for HIV, the UK, Bulgaria, Slovakia and Romania being the notable exceptions.

The overwhelming evidence of the benefits of HIV testing both at the individual and the community level described in the scientific literature is also mentioned in these policy documents. As all major international testing guidelines acknowledge, HIV testing on its own cannot be the final goal, and it is essential to link testing with care, support and treatment, ensuring a clear referral pathway for those who test positive. This is not the case across the region, especially for migrants of uncertain legal status. As the economic crisis has worsened across the European region, some countries have implemented a reduction in their expenditure through different policies like decreasing the total public spending in medical care or the volume and quality of care. Recent data from OECD show that health spending per person and as a percentage of GDP fell across the European Union in 2010. This is the first time that health spending has fallen in Europe since 1975. In Spain, health spending fell 0.9% in 2010, compared with an average annual growth rate of 4.6% between 2000 and 2009. Governments find themselves under pressure to protect funding for acute care and are cutting other expenditures such as public health and prevention programmes. In Spain, for example, measures in 2012 have been proposed to deny health care to migrants of uncertain legal status. Perea-Molina and Pulido have carried out an analysis about the consequences of this measure and stated that the expected savings in the short term would be much lower than expected savings in the long term. They showed its impact on the country’s public health would be negative, increasing mortality and morbidity owing to communicable diseases and increasing spending in the medium and long term. Owing to this expertise initiative, finally the policy has not been implemented. This type of policy is thought to undermine health system goals; therefore, comprehensive and coherent policies are needed to improve health.

Unawareness of national HIV testing policies by health care professionals could be a barrier to put in practice recommendations and could explain the low and variable coverage of known groups at risk.

The EU/EFTA is a heterogeneous area conformed by 31 countries with different cultural, socio-economic, political, legal and migratory contexts. Besides, there are important differences in the epidemiology of HIV between countries, as well as remarkable disparities in the health systems and social welfare structures. Because the absolute and relative contribution of migrants and ethnic minorities to the number of HIV and AIDS cases also varies greatly between different Member States, the legislation and the practices towards testing these groups for HIV must, necessarily, be different too. Also, it is likely that fear of further stigmatization may have deterred countries’ public health authorities to identify migrants as key populations for HIV testing. Nevertheless, migrants from high HIV prevalence settings should be included as a key group to be offered HIV testing and care in national policy documents as the first step to decrease the undiagnosed fraction among migrants in the EU region, provided that core principles of HIV testing programmes are guaranteed.

In analysing policies and recommendations from different countries, we observed inconsistencies within single countries. A number of countries have no guidelines for HIV testing; others are planning to develop them; and some are in the process of updating their HIV/AIDS Plans. This may explain the discrepancies between the information provided directly to us by the country representatives and the information we retrieved from the documents. Data provided by the key informants were invaluable, as it was a direct source of information, especially relevant in the case of countries with languages unknown by the research team.

Moving towards the normalization of HIV testing with universal strategies in selected contexts, as for example promoting universal HIV testing in some areas with high HIV prevalence rates, should

### Table 3 Groups of migrants targeted for HIV testing

| Country* | Groups mentioned |
|----------|------------------|
| Belgium  | Migrant population |
| Bulgaria | Refugees and asylum seekers; persons from high HIV prevalence countries and their sexual partners |
| Denmark  | Persons from Africa, Asia, South America and Eastern Europe |
| France   | High HIV endemic countries, especially SSA, Caribbean |
| Iceland  | All migrants intending to stay for >1 year in Iceland as part of general health screening |
| Lithuania| Migrant populations |
| Luxembourg| People from SSA, Asia, Eastern Europe. Target groups of residents with foreign origin (especially Luxophon community) |
| Netherlands| High HIV prevalence countries (SSA, Surinam, Netherlands Antilles, South America, Eastern Europe and Asia); partners of people from HIV endemic area |
| Norway   | People from high HIV endemic countries |
| Poland   | All migrants are offered to have a voluntary HIV test on arrival as part of general health screening. |
| Slovakia | All migrants to have an HIV test on arrival as part of general health screening |
| Sweden   | People from high endemic areas |
| Switzerland| People from countries with generalized epidemic |
| UK       | People from high HIV prevalence countries |

*By the beginning of 2013, Greece will publish new HIV testing procedures that recommends HIV testing in individuals originated from generalized epidemic countries (Sub-Saharan Africa) and men and women who report sexual contacts with individuals originated from high prevalence countries.
not substitute HIV testing programmes for groups more at risk, such as migrants from HIV endemic countries. Nevertheless, a prioritization of resources based on cost-economic analyses and knowledge about implementation is needed.\textsuperscript{35}

The various documents reviewed call to broaden the scope of health settings performing the HIV test, to strengthen proactive testing strategies, to put in place outreach programmes based on community approaches, like offering the test where people live, work or spend their leisure time, expanding testing hours and involving NGOs and Community Based Organizations through Point of care testing and rapid testing. The UK Health Protection Agency (now Public Health England) recommended giving support to primary care practitioners to assess the need for HIV testing in migrants.\textsuperscript{56} In fact, General Practitioners are also at the centre of HIV testing strategies in Germany, the Netherlands, Norway, Spain and Switzerland,\textsuperscript{42} and their perseverance has proved to be a key factor in increasing the uptake of HIV testing.\textsuperscript{59}

The objective of this study was not to exhaustively assess to what extent mandatory HIV testing is applied to migrants. However, in reviewing policy documents, it can be concluded that policies in some countries may more or less inadvertently facilitate this practice. A number of international testing guidelines, particularly those from ECDC\textsuperscript{17} and WHO,\textsuperscript{24} strongly advice against mandatory HIV testing for migrants.

In summary, most documents consider migrants as disproportionately affected by HIV infection, and the benefits of early diagnosis are highlighted. National policy documents should recommend voluntary HIV testing for migrants as the first step to decrease the higher undiagnosed fraction in this population in the EU/EFTA region. Although national HIV testing policies are heterogeneous across the countries in the European region, HIV testing approaches must rely on the pillar that testing must be linked to care as clearly stated in the ECDC HIV testing Guidelines.\textsuperscript{17} The fact that there are countries which do not provide universal HIV prevention, treatment and care for migrants of uncertain legal status challenges the ethics and the effectiveness in the application of the pro-active HIV testing and are a deterrent for the control of an important public health problem in the region.

Supplementary data

Supplementary data are available at EURPUB online.

Acknowledgements

We are grateful to all the National Informants for their valuable input into this work.

Funding

European Centre for Disease Prevention and Control, Spanish Network of HIV/AIDS Research [RIS- RD06/0006] and the Biomedical Research Centre Network for Epidemiology and Public Health [CIBER de Epidemiología y Salud Pública].

Conflicts of interest: None declared.

Key points

- Countries need to offer strategies and structures to provide adequate and accessible HIV testing according to their specific context, to be able to reduce the higher fraction of undiagnosed infection in this population.
- Linking HIV testing with treatment and care, regardless of migrants’ legal status, is key to ensure the effectiveness of pro-active testing strategies and to guarantee the benefits of timely treatment.

References

1. del Amo I, Likatavicius G, Perez-Cachafeiro S, et al. The epidemiology of HIV and AIDS reports in migrants in the 27 European Union countries, Norway and Iceland: 1999-2006. \textit{Euro J Public Health} 2011;21:620–6.
2. European Centre for Disease Prevention and Control (ECDC) and World Health Organization (WHO). HIV/AIDS surveillance in Europe 2010. 2011. Available at: http://www.ecdc.europa.eu/en/publications/Publications/111129_SUR_Annual_HIV_Report.pdf (15 November 2012, date last accessed).
3. European Centre for Disease Prevention and Control (ECDC). Implementing the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2010 Progress Report. 2010. Available at: http://ecdc.europa.eu/en/publications/Publications/1009_SPR_Dublin_declaration_progress_report.pdf (24 September 2012, date last accessed).
4. Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. \textit{J EpidemiolCommunity Health} 2004;58:441–45.
5. del Amo I, Broering G, Fenton K. HIV health experiences among migrant Africans in Europe: how are we doing? AIDS 2003;17:2261–3.
6. European Centre for Disease Prevention and Control (ECDC). Improving HIV data comparability in migrant populations and ethnic minorities in EU/EAEA/EFTA countries: findings from a literature review and expert panel. 2011. Available at: http://www.ecdc.europa.eu/en/publications/Publications/1108_TER_Improving_HIV_data_comparability_in_migrants.pdf (24 September 2012, date last accessed).
7. International Organization for Migration (IOM), IOM guide for HIV counsellors. 2006. Available at: http://www.iom.int/jahia/webdav/site/myjhiasite/shared/shared/main/site/published_docs/brochures_and_info_sheets/HIV%20counselors%20GUIDE%20FINAL_Apr2006%20(4).pdf (15 November 2012, date last accessed).
8. Monge S, Alejos B, Dronda F, et al. Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain. \textit{HIV Med} 2013;14:273–83.
9. Burns FM, Imrie JY, Nazroo J, et al. Why the(y) wait? Key informant understandings of factors contributing to late presentation and poor utilization of HIV health and social care services by African migrants in Britain. \textit{AIDS Care} 2007; 19:102–8.
10. Fakoya I, Reynolds R, Caswell G, Shiripinda I. Barriers to HIV testing for migrant black Africans in Western Europe. \textit{HIV Med} 2008;9(Suppl 2):23–5.
11. Post A, Elford J, Imrie J, et al. Social, behavioural, and intervention research among people of Sub-Saharan African origin living with HIV in the UK and Europe: literature review and recommendations for intervention. \textit{AIDS Behav} 2008;12:170–94.
12. Alvarez-del Arco D, Monge S, Azcoaga Lorenzo A, et al. HIV testing and counselling for migrant populations living in high-income countries: A systematic review. \textit{Euro J Public Health} 2012; doi: 10.1093/eurpub/cks130.
13. Lopez-Quintero C, Shaheskull R, Neumark YD. Barriers to HIV-testing among Hispanics in the United States: analysis of the National Health Interview Survey, 2000. \textit{AIDS Patient Care STDS} 2005;19:627–83.
14. Chadborn TR, Delpech VC, Sabin CA, et al. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004). \textit{AIDS} 2006;20:2371–79.
15. Caro-Murillo AM, Gutierrez F, Manuel RJ, et al. HIV infection in immigrants in Spain: Epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004-2006)[in Spanish]. \textit{Enferm Infect Microbiol Clin} 2009;27:380–8.
16. Platform for international cooperation and undocumented migrants (PICUM). Access to Health Care for Undocumented Migrants in Europe. 2007. Available at: http://picum.org/picum.org/uploads/file_/Access_to_Health_Care_for_Undocumented_Migrants.pdf (24 September 2012, date last accessed).
17. European Centre for Disease Prevention and Control (ECDC). HIV testing: increasing uptake and effectiveness in the European Union. 2010. Available at:
18 Conseil constitutionnel. LOI no 98-349 du 11 mai 1998 relative à l’entrée et au séjour des étrangers en France et au droit d’asile. 1998. Available at: http://www.legifrance.gouv.fr/seeText.do?reprise=true&page=1. (30 October 2012, date last accessed).

19 Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010;5:e11068.

20 European Centre for Diseases Prevention and Control (ECDC). Migrant health: Background note to the ‘ECDC Report on migration and infectious diseases in the EU’. Technical report. 2009. Available at: http://www.episouth.org/doc/_documents/0907_TER_Migrant_health_Background_note.pdf (15 September 2012, date last accessed).

21 National Institute of Allergy and Infectious Diseases (NIAID). Treating HIV-infected People with Antiretrovirals Protects Partners from Infection. 2011. Available at: http://www.niaid.nih.gov/news/newsreleases/2011/pages/hptn052.aspx (24 September 2012, date last accessed).

22 Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004;18: 81–8.

23 Quinn TC, Waver MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921–9.

24 World Health Organization (WHO). Scaling up HIV testing and counselling in the WHO European Region as an essential component of efforts to achieve universal access to HIV prevention, treatment, care and support. 2010. Available at: http://www.euro.who.int/__data/assets/pdf_file/0007/85489/E93715.pdf (12 September 2012, date last accessed).

25 Centres of Disease Control. Recommended Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings. 2010. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm (10 October 2012, date last accessed).

26 UNAIDS and World Health Organization (WHO). UNAIDS/WHO Policy Statement on HIV Testing. 2004. Available at: http://www.who.int/rtcp/research_ethics/hivtestingpolicy_en.pdf (24 September 2012, date last accessed).

27 Mladovsky P, Srivastava D, Cylus J, et al. Health policy responses to the financial crisis in Europe. 2012. Available at: http://www.euro.who.int/__data/assets/pdf_file/0009/170865/e96643.pdf (24 September 2012, date last accessed).

28 Organisation for Economic Co-operation and Development (OECD). Health at a Glance: Europe. 2012. Available at: http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2012_9789264183896-en (10 October 2012, date last accessed).

29 Spanish Head of State. Royal Decree-Law 12/2012 of 20th April. 2012. Available at: http://www.boe.es/boe/dias/2012/04/24/pdfs/BOE-A-2012-5403.pdf (15 September 2012, date last accessed).

30 Perez-Molina JA, Pulido OF. Assessment of the impact of the new health legislation on illegal immigrants in Spain: The case of human immunodeficiency virus infection [in Spanish]. Enferm Infecc Microbiol Clin 2012;30:472–8.

31 Rohregger B. Social determinants of health: The role of social protection in addressing social inequalities in healthAvailable at: http://www.gtz.de/de/dokumente/gtz2011-en-social-determinants-of-health.pdf. (10 September 2012, date last accessed).

32 Monge S, Del Romero J, Rodriguez C, et al. Socio-demographic factors associated with the progression of HIV infection and the impact of HAART in a seroconverter cohort in Madrid (1986-2009) [in Spanish]. Enferm Infecc Microbiol Clin 2012;30: 117–23.

33 Deblonde J, Claey s P, Temmerman M. Antenatal HIV screening in Europe: a review of policies. Eur J Public Health 2007;17:414–8.

34 Mounier-Jack S, Nielsen S, Coker R. HIV testing strategies across European countries. HIV Med 2008;9(Suppl 2):13–9.

35 Khotenashvili L, Matic S, Lazarus J. HIV testing and counselling policies and practices in Europe: lessons learned, ways forward. HIV Med 2008;9(Suppl 2):30–3.

36 Health Protection Agency Centre for Infections. A Complex Picture. 2006. Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947365435 (30 September 2012, date last accessed).

37 Deblonde J, De KP, Hamers FF, et al. Barriers to HIV testing in Europe: a systematic review. Eur J Public Health 2010;20:422–32.

Appendix 1

Study working group

Álvarez-del Arco D, Monge S, Caro-Murillo AM, Ramírez-Rubio O, Azcoaga A, González C, Hernando V, Alejos B, Pérez-Cachaféiro S, Rio I, Rivero-Montesdeoca Y, Belza M, Bolúmar F, Noori T and Del Amo J.